Welcome to our dedicated page for NEKTAR THERAPEUTICS SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics (NKTR) filed a Form 144 notifying the proposed sale of 1,573 common shares acquired on 08/15/2025 through restricted stock vesting. The filer lists an aggregate market value of $41,826.23 for those shares and reports approximately 19,018,573 shares outstanding. The proposed sale date is 08/19/2025 on NASDAQ, and the securities were recorded as compensation. The filing also discloses that Howard Robin sold 23,208 common shares on 05/19/2025 for gross proceeds of $15,579.54. The notice includes the standard representation that the signer does not possess undisclosed material adverse information.
Nektar Therapeutics (NKTR) filed a Form 144 reporting a proposed sale of 676 shares of common stock held at Fidelity Brokerage Services. The filing states the shares were acquired on 08/15/2025 upon restricted stock vesting and were paid as compensation. The filer lists an approximate sale date of 08/19/2025 and an aggregate market value of $17,974.90, with 19,018,573 shares outstanding and the intended exchange listed as NASDAQ. The form indicates no securities sold by the filer in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Nektar Therapeutics (NKTR) Form 144 notice reports a proposed sale of 725 common shares held in a brokerage account at Fidelity Brokerage Services. The shares were acquired through restricted stock vesting on 08/15/2025 and were paid as compensation. The filer lists an approximate sale date of 08/19/2025 on the NASDAQ; the aggregate market value at that date is shown as $19,277.83. The filing states there were no securities sold in the past three months by the same person and includes the standard representation that the seller knows of no undisclosed material adverse information.
Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 709,761 shares of Nektar Therapeutics common stock, representing 5.72% of the class as of June 30, 2025. The filing states all shares are held by funds and separately managed accounts under Nantahala's control and that each reporting person has shared voting and dispositive power over those shares and no sole voting or dispositive power. The statement certifies the shares were acquired and are held in the ordinary course of business and not with the purpose of changing or influencing control of the issuer.
Nektar Therapeutics has a group of related reporting persons — TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and individual Chen Yu — that together report beneficial ownership of 1,933,333 shares of common stock, representing 9.3% of the class on a fully reported basis. The disclosed position consists of 266,666 shares held of record and 1,666,667 shares issuable upon exercise of pre-funded warrants held of record by the reporting vehicle. The filing states the holdings are shared voting and dispositive power and references 19,018,573 shares outstanding used in the percentage calculation. The statement confirms the position was not acquired to change or influence control.